Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232-0493, USA.
J Cardiovasc Transl Res. 2011 Oct;4(5):658-71. doi: 10.1007/s12265-011-9300-4. Epub 2011 Jul 13.
Although artificial prostheses for diseased heart valves have been around for several decades, viable heart valve replacements have yet to be developed due to their complicated nature. The majority of research in heart valve replacement technology seeks to improve decellularization techniques for porcine valves or bovine pericardium as an effort to improve current clinically used valves. The drawback of clinically used valves is that they are nonviable and thus do not grow or remodel once implanted inside patients. This is particularly detrimental for pediatric patients, who will likely need several reoperations over the course of their lifetimes to implant larger valves as the patient grows. Due to this limitation, additional biomaterials, both synthetic and natural in origin, are also being investigated as novel scaffolds for tissue-engineered heart valves, specifically for the pediatric population. Here, we provide a brief overview of valves in clinical use as well as of the materials being investigated as novel tissue-engineered heart valve scaffolds. Additionally, we focus on natural-based biomaterials for promoting cell behavior that is indicative of the developmental biology process that occurs in the formation of heart valves in utero, such as epithelial-to-mesenchymal transition or transformation. By engineering materials that promote native developmental biology cues and signaling, while also providing mechanical integrity once implanted, a viable tissue-engineered heart valve may one day be realized. A viable tissue-engineered heart valve, capable of growing and remodeling actively inside a patient, could reduce risks and complications associated with current valve replacement options and improve overall quality of life in the thousands of patients who received such valves each year, particularly for children.
尽管用于病变心脏瓣膜的人工假体已经存在了几十年,但由于其复杂性,仍然尚未开发出可行的心脏瓣膜替换物。心脏瓣膜替换技术的大多数研究都致力于改善猪瓣膜或牛心包的脱细胞技术,以改进目前临床使用的瓣膜。临床使用的瓣膜的缺点是它们不可存活,因此一旦植入患者体内就不会生长或重塑。这对儿科患者尤其不利,因为他们一生中可能需要多次手术来植入更大的瓣膜,因为患者在成长。由于这种局限性,还在研究其他生物材料,包括合成材料和天然材料,作为组织工程心脏瓣膜的新型支架,特别是针对儿科人群。在这里,我们简要介绍了临床使用的瓣膜以及作为新型组织工程心脏瓣膜支架正在研究的材料。此外,我们还专注于天然生物材料,以促进细胞行为,这种细胞行为类似于在子宫内形成心脏瓣膜过程中发生的发育生物学过程,例如上皮细胞到间充质的转变或转化。通过设计能够促进固有发育生物学线索和信号的材料,同时在植入后提供机械完整性,有朝一日可能会实现可行的组织工程心脏瓣膜。一个可行的组织工程心脏瓣膜,可以在患者体内积极生长和重塑,可能会降低与当前瓣膜替换选择相关的风险和并发症,并提高每年接受此类瓣膜的数千名患者的整体生活质量,特别是对儿童而言。